Verquvo — United Healthcare

Initial criteria

• Diagnosis of symptomatic heart failure
• Ejection fraction is less than 45 percent
• Heart failure classified as NYHA Class II OR NYHA Class III OR NYHA Class IV
• Hospitalization for heart failure within the past 6 months OR outpatient IV diuretics for heart failure within the past 3 months

Reauthorization criteria

• Documentation of a positive clinical response to Verquvo therapy

Approval duration

12 months